Clinical trial

Value of Heart Rate Lowering Therapy in Acute Myocarditis

Name

VOHRLTIAM

Description

To study the value of heart rate lowering therapy "pharmacological rest" on the short term in cases of myocarditis without LV dysfunction.

Trial arms

Trial start

2024-04-01

Estimated PCD

2025-04-01

Trial end

2025-06-01

Status

Recruiting

Treatment

Ivabradine

heart rate lowering therapy

Arms:

Conventional ttt PLUS Ivabradine.

Size

150

Primary endpoint

Value of Heart Rate Lowering Therapy in Acute Myocarditis

baseline

Eligibility criteria

Inclusion Criteria: * Adults: ≥18 years of age. * Presentation: at least one of the following: * Myopericarditis/ACS-like * MINOCA * Arrhythmias: brady or tachyarrhythmias. * Unexplained compensated acute cardiomyopathy (excluded ischemic, valvular, hypertensive, metabolic, and toxic causes of cardiomyopathy as indicated clinically). * TTE: LVEF\>40% * CMR-confirmed myo(peri)carditis (Lake Louise criteria) Exclusion Criteria: * • Rheumatic carditis. * Connective tissue diseases (-ve ANA). * Cancer chemotherapy. * Toxicity from immunotherapy. * Vaccine-related myocarditis. * Presence of coronary artery disease. * Peripartum (occurring during the last month of pregnancy or within 5 months after delivery) * ECG: atrial fibrillation/flutter. * Resuscitated sudden death. * Early/initial phase of decompensated heart failure. * Tamponade complicating pericarditis unless successfully managed.

Protocol

{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 150, 'type': 'ESTIMATED'}}

Updated at

2024-03-15

1 organization

1 product

1 indication

Organization

Assiut University

Product

Ivabradine

Indication

Myocarditis